Apoptosis: Why and how does it occur in biology?

Cell Biochemistry and Function

Volumn 29, Issue 6, 2011, Pages 468-480

  Ulukaya, Engin ^a   Acilan, Ceyda ^b   Yilmaz, Yusuf ^c  

^a ULUDAG UNIVERSITY   (Turkey)

^b SCIENTIFIC AND TECHNOLOGICAL RESEARCH COUNCIL OF TURKEY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Apoptosis inducing factors (AIFs); Bcl 2 family; Caspase; Inhibitor of apoptosis proteins (IAPs); Necrosis; Programmed cell death

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; BAG 1 PROTEIN; BIM PROTEIN; CASPASE; CASPASE INHIBITOR; CELLULAR APOPTOSIS SUSCEPTIBILITY PROTEIN; CERAMIDE; FAS ANTIBODY; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GRANZYME; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; NAVITOCLAX; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OBATOCLAX; PERFORIN; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; PROTEIN KINASE B INHIBITOR; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS ANTAGONIST;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; APOPTOSIS; CAENORHABDITIS ELEGANS; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL ACTIVATION; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL GROWTH; CELL PROTECTION; CELL STRESS; CELL SURVIVAL; CELL SWELLING; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DEPHOSPHORYLATION; DISEASE COURSE; DNA DAMAGE; DNA FRAGMENTATION; DRUG BINDING; DRUG MECHANISM; DRUG SYNTHESIS; ENDOMETRIUM; ENZYME ACTIVATION; ENZYME SUBSTRATE; EPSTEIN BARR VIRUS; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INTERNUCLEOSOMAL DNA FRAGMENTATION; KERATINOCYTE; MITOCHONDRIAL ACTIVATION; MITOSIS; MOLECULAR BIOLOGY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NECROSIS; NEOPLASM; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OLIGOMERIZATION; ORGAN TRANSPLANTATION; OXIDATIVE STRESS; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEPHOSPHORYLATION; PROTEIN SECRETION; REVIEW; THYMUS; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; CASPASES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NECROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

INTRACISTERNAL A-PARTICLES;

EID: 80051668693     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1774     Document Type: Review

References (207)

1. Ahuja V, Dieckgraefe BK, Anant S. Molecular biology of the small intestine. Curr Opin Gastroenterol 2006; 22: 90-94.
2. Kiernan JA. Production and life span of cutaneous mast cells in young rats. J Anat 1979; 128: 225-238.
3. Nadal-Ginard B, Anversa P, Kajstura J, Leri A. Cardiac stem cells and myocardial regeneration. Novartis Found Symp 2005; 265: 142-154; discussion 155-147, 204-111.
4. Recknor JBSKM. Nerve Regeneration: Tissue Engineering Strategies. Taylor & Francis: New York, 2006.
5. Mattson MP. Apoptotic and anti-apoptotic synaptic signaling mechanisms. Brain Pathol 2000; 10: 300-312.
6. Mondello C, Scovassi AI. Apoptosis: a way to maintain healthy individuals. Subcell Biochem 2011; 50: 307-323.
7. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
8. Cotter TG, Lennon SV, Glynn JG, Martin SJ. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumour and normal cells. Anticancer Res 1990; 10: 1153-1159.
9. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
10. Majno G, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995; 146: 3-15.
11. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000; 45: 528-537.
12. Tepper AD, Ruurs P, Wiedmer T, et al. Sphingomyelin hydrolysis to ceramide during the execution phase of apoptosis results from phospholipid scrambling and alters cell-surface morphology. J Cell Biol 2000; 150: 155-164.
13. Nathan C, Ding A. Nonresolving inflammation. Cell 2011; 140: 871-882.
14. Montague JW, Cidlowski JA. Cellular catabolism in apoptosis: DNA degradation and endonuclease activation. Experientia 1996; 52: 957-962.
15. Vance JE, Steenbergen R. Metabolism and functions of phosphatidylserine. Prog Lipid Res 2005; 44: 207-234.
16. Mourdjeva M, Kyurkchiev D, Mandinova A, et al. Dynamics of membrane translocation of phosphatidylserine during apoptosis detected by a monoclonal antibody. Apoptosis 2005; 10: 209-217.
17. Chinnaiyan AM. The apoptosome: heart and soul of the cell death machine. Neoplasia 1999; 1: 5-15.
18. Mattson MP, Chan SL. Calcium orchestrates apoptosis. Nat Cell Biol 2003; 5: 1041-1043.
19. Hoetelmans RW, Vahrmeijer AL, van Vlierberghe RL, et al. The role of various Bcl-2 domains in the anti-proliferative effect and modulation of cellular glutathione levels: a prominent role for the BH4 domain. Cell Prolif 2003; 36: 35-44.
20. Kischkel FC, Lawrence DA, Chuntharapai A, et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
21. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992; 69: 119-128.
22. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247-3259.
23. Alsafadi S, Tourpin S, Andre F, Vassal G, Ahomadegbe JC. P53 family: at the crossroads in cancer therapy. Curr Med Chem 2009; 16: 4328-4344.
24. Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008; 7: 1036-1046.
25. Janicke RU, Ng P, Sprengart ML, Porter AG. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis. J Biol Chem 1998; 273: 15540-15545.
26. Ruchaud S, Korfali N, Villa P, et al. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J 2002; 21: 1967-1977.
27. Gershoni M, Templeton AR, Mishmar D. Mitochondrial bioenergetics as a major motive force of speciation. BioEssays 2009; 31: 642-650.
28. Breckenridge DG, Germain M, Mathai JP, Nguyen M, Shore GC. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 2003; 22: 8608-8618.
29. Orrenius S, McCabe MJ, Jr., Nicotera P. Ca(2+)-dependent mechanisms of cytotoxicity and programmed cell death. Toxicol Lett 1992; 64-65 Spec No: 357-364.
30. Hand D, Bungay PJ, Elliott BM, Griffin M. Activation of transglutaminase at calcium levels consistent with a role for this enzyme as a calcium receptor protein. Biosci Rep 1985; 5: 1079-1086.
31. Barbado M, Fablet K, Ronjat M, De Waard M. Gene regulation by voltage-dependent calcium channels. Biochim Biophys Acta 2009; 1793: 1096-1104.
32. Nakagawa T, Yuan J. Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis. J Cell Biol 2000; 150: 887-894.
33. Zimmerman UJ, Schlaepfer WW. Characterization of a brain calcium-activated protease that degrades neurofilament proteins. Biochemistry 1982; 21: 3977-3982.
34. Glenney JR, Jr., Bretscher A, Weber K. Calcium control of the intestinal microvillus cytoskeleton: its implications for the regulation of microfilament organizations. Proc Natl Acad Sci USA 1980; 77: 6458-6462.
35. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994; 68: 4262-4273.
36. Forte E, Luftig MA. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J Virol 2009; 83: 2491-2499.
37. Zhao LY, Liao D. Sequestration of p53 in the cytoplasm by adenovirus type 12 E1B 55-kilodalton oncoprotein is required for inhibition of p53-mediated apoptosis. J Virol 2003; 77: 13171-13181.
38. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
39. Alarcon-Vargas D, Ronai Z. p53-Mdm2--the affair that never ends. Carcinogenesis 2002; 23: 541-547.
40. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132-1136.
41. Joza N, Susin SA, Daugas E, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001; 410: 549-554.
42. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489.
43. Enari M, Sakahira H, Yokoyama H, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43-50.
44. Hunot S, Flavell RA. Apoptosis. Death of a monopoly? Science 2001; 292: 865-866.
45. Hardy JA, Lam J, Nguyen JT, O'Brien T, Wells JA. Discovery of an allosteric site in the caspases. Proc Natl Acad Sci USA 2004; 101: 12461-12466.
46. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis 2002; 7: 313-319.
47. Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001; 276: 7320-7326.
48. Okinaga T, Kasai H, Tsujisawa T, Nishihara T. Role of caspases in cleavage of lamin A/C and PARP during apoptosis in macrophages infected with a periodontopathic bacterium. J Med Microbiol 2007; 56: 1399-1404.
49. Boulares AH, Yakovlev AG, Ivanova V, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999; 274: 22932-22940.
50. Bharti AC, Takada Y, Aggarwal BB. PARP cleavage and caspase activity to assess chemosensitivity. Methods Mol Med 2005; 111: 69-78.
51. Mao PL, Jiang Y, Wee BY, Porter AG. Activation of caspase-1 in the nucleus requires nuclear translocation of pro-caspase-1 mediated by its prodomain. J Biol Chem 1998; 273: 23621-23624.
52. Kallio MJ, Nieminen M, Eriksson JE. Human inhibitor of apoptosis protein (IAP) survivin participates in regulation of chromosome segregation and mitotic exit. FASEB J 2001; 15: 2721-2723.
53. Kidd VJ, Lahti JM, Teitz T. Proteolytic regulation of apoptosis. Semin Cell Dev Biol 2000; 11: 191-201.
54. Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-535.
55. Ghavami S, Hashemi M, Ande SR, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009; 46: 497-510.
56. Ando K, Hiroishi K, Kaneko T, et al. Perforin, Fas/Fas ligand, and TNF-alpha pathways as specific and bystander killing mechanisms of hepatitis C virus-specific human CTL. J Immunol 1997; 158: 5283-5291.
57. Thiery J, Keefe D, Saffarian S, et al. Perforin activates clathrin- and dynamin-dependent endocytosis, which is required for plasma membrane repair and delivery of granzyme B for granzyme-mediated apoptosis. Blood 2011; 115: 1582-1593.
58. Brinkmann U, Brinkmann E, Gallo M, Pastan I. Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. Proc Natl Acad Sci USA 1995; 92: 10427-10431.
59. Praveen K, Leary JH, 3rd, Evans DL, Jaso-Friedmann L. Molecular cloning of cellular apoptosis susceptibility (CAS) gene in Oreochromis niloticus and its proposed role in regulation of non-specific cytotoxic cell (NCC) functions. Fish Shellfish Immunol 2006; 20: 647-655.
60. Behrens P, Brinkmann U, Wellmann A. CSE1L/CAS: its role in proliferation and apoptosis. Apoptosis 2003; 8: 39-44.
61. Brinkmann U. CAS, the human homologue of the yeast chromosome-segregation gene CSE1, in proliferation, apoptosis, and cancer. Am J Hum Genet 1998; 62: 509-513.
62. Brinkmann U, Gallo M, Polymeropoulos MH, Pastan I. The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. Genome Res 1996; 6: 187-194.
63. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 2011; 17: 616-623.
64. Degli-Esposti M. To die or not to die--the quest of the TRAIL receptors. J Leukoc Biol 1999; 65: 535-542.
65. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113.
66. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574-577.
67. Collison A, Foster PS, Mattes J. Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol 2009; 36: 1049-1053.
68. Martin DA, Siegel RM, Zheng L, Lenardo MJ. Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J Biol Chem 1998; 273: 4345-4349.
69. Sprick MR, Weigand MA, Rieser E, et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000; 12: 599-609.
70. Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704-3714.
71. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
72. Bennett MW, O'Connell J, O'Sullivan GC, et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-5675.
73. Kozlowski M, Kowalczuk O, Sulewska A, et al. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus. Folia Histochem Cytobiol 2007; 45: 199-204.
74. Mann B, Gratchev A, Bohm C, et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999; 79: 1262-1269.
75. Nagao M, Nakajima Y, Hisanaga M, et al. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 1999; 30: 413-421.
76. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res 2001; 7: 1282-1286.
77. Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 1998; 153: 1947-1956.
78. Kanda Y, Chiba S, Tanaka Y, et al. Increased serum soluble Fas ligand associated with recurrent B-cell non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Leuk Lymphoma 1999; 34: 625-628.
79. Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099-1109.
80. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003; 116: 4077-4085.
81. Zinkel SS, Hurov KE, Ong C, et al. A role for proapoptotic BID in the DNA-damage response. Cell 2005; 122: 579-591.
82. Gross A. BID as a double agent in cell life and death. Cell Cycle 2006; 5: 582-584.
83. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathophysiology 2000; 7: 153-163.
84. Hasan NM, Adams GE, Joiner MC. Effect of serum starvation on expression and phosphorylation of PKC-alpha and p53 in V79 cells: implications for cell death. Int J Cancer 1999; 80: 400-405.
85. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-241.
86. Motyka B, Korbutt G, Pinkoski MJ, et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 2000; 103: 491-500.
87. Darmon AJ, Nicholson DW, Bleackley RC. Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B. Nature 1995; 377: 446-448.
88. Pettus BJ, Chalfant CE, Hannun YA. Ceramide in apoptosis: an overview and current perspectives. Biochim Biophys Acta 2002; 1585: 114-125.
89. Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994; 180: 525-535.
90. Moulin M, Carpentier S, Levade T, Arrigo AP. Potential roles of membrane fluidity and ceramide in hyperthermia and alcohol stimulation of TRAIL apoptosis. Apoptosis 2007; 12: 1703-1720.
91. Quillet-Mary A, Jaffrezou JP, Mansat V, et al. Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem 1997; 272: 21388-21395.
92. Yu ZF, Nikolova-Karakashian M, Zhou D, et al. Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J Mol Neurosci 2000; 15: 85-97.
93. Magnoni C, Euclidi E, Benassi L, et al. Ultraviolet B radiation induces activation of neutral and acidic sphingomyelinases and ceramide generation in cultured normal human keratinocytes. Toxicol In Vitro 2002; 16: 349-355.
94. Yen CL, Mar MH, Meeker RB, Fernandes A, Zeisel SH. Choline deficiency induces apoptosis in primary cultures of fetal neurons. FASEB J 2001; 15: 1704-1710.
95. Delpy E, Hatem SN, Andrieu N, et al. Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res 1999; 43: 398-407.
96. Wang C, Youle RJ. The role of mitochondria in apoptosis*. Annu Rev Genet 2009; 43: 95-118.
97. Jeong SY, Seol DW. The role of mitochondria in apoptosis. BMB Rep 2008; 41: 11-22.
98. Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells 1998; 3: 697-707.
99. Fletcher JI, Huang DC. BH3-only proteins: orchestrating cell death. Cell Death Differ 2006; 13: 1268-1271.
100. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 2003; 7: 249-257.
101. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998; 8: 324-330.
102. Sattler M, Liang H, Nettesheim D, et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997; 275: 983-986.
103. Sugioka R, Shimizu S, Funatsu T, et al. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 2003; 22: 8432-8440.
104. Letai A, Bassik MC, Walensky LD, et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
105. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525-535.
106. Merino D, Giam M, Hughes PD, et al. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 2009; 186: 355-362.
107. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green DR. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 2005; 309: 1732-1735.
108. Leber B, Lin J, Andrews DW. Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene 2011; 29: 5221-5230.
109. Hoetelmans RW, Van de Velde CJ, Van Dierendonck JH. The presence of 19-kDa Bcl-2 in dividing cells. Cell Prolif 2003; 36: 293-306.
110. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-251.
111. Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999; 18: 2330-2341.
112. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 1999; 399: 483-487.
113. Shimizu S, Ide T, Yanagida T, Tsujimoto Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J Biol Chem 2000; 275: 12321-12325.
114. Tsuruta F, Sunayama J, Mori Y, et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 2004; 23: 1889-1899.
115. Ohtsuka T, Ryu H, Minamishima YA, et al. ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nat Cell Biol 2004; 6: 121-128.
116. Schneider-Jakob S, Corazza N, Badmann A, et al. Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid. Cell Death Disease 2010; 1: e86. DOI:10.1038/cddis.2010.1066.
117. Song G, Chen GG, Hu T, Lai PB. Bid Stands at the Crossroad of Stress-response Pathways. Curr Cancer Drug Targets 2010; 10: 584-592.
118. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
119. Green DR. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000; 102: 1-4.
120. Bai L, Cao CP, Mao GP. Mechanism of hepatocytes apoptosis induced by the proapoptosis protein Bid. Chin J Dig Dis 2004; 5: 175-180.
121. Wei MC, Lindsten T, Mootha VK, et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14: 2060-2071.
122. Kamer I, Sarig R, Zaltsman Y, et al. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 2005; 122: 593-603.
123. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002; 1: 989-997.
124. Hu H, Jiang C, Li G, Lu J. PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells. Carcinogenesis 2005; 26: 1374-1381.
125. Zhao S, Konopleva M, Cabreira-Hansen M, et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 2004; 18: 267-275.
126. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003; 8: 413-450.
127. Kim H, Tu HC, Ren D, et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 2009; 36: 487-499.
128. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008; 27: 6194-6206.
129. Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell 1996; 87: 171.
130. Sandu C, Gavathiotis E, Huang T, Wegorzewska I, Werner MH. A mechanism for death receptor discrimination by death adaptors. J Biol Chem 2005; 280: 31974-31980.
131. Rodriguez J, Lazebnik Y. Caspase-9 and APAF-1 form an active holoenzyme. Genes Dev 1999; 13: 3179-3184.
132. Kuida K, Haydar TF, Kuan CY, et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998; 94: 325-337.
133. Cande C, Cohen I, Daugas E, et al. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie 2002; 84: 215-222.
134. Colussi PA, Kumar S. Targeted disruption of caspase genes in mice: what they tell us about the functions of individual caspases in apoptosis. Immunol Cell Biol 1999; 77: 58-63.
135. Mak T. The execution complex of apoptosis. Biochemica 2000; 1: 39-41.
136. Denis F, Rheaume E, Aouad SM, et al. The role of caspases in T cell development and the control of immune responses. Cell Mol Life Sci 1998; 54: 1005-1019.
137. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 1999; 68: 383-424.
138. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316.
139. Ekedahl J, Joseph B, Grigoriev MY, et al. Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. Exp Cell Res 2002; 279: 277-290.
140. Gill C, Dowling C, O'Neill AJ, Watson RW. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer 2009; 8: 39.
141. Takahashi R, Deveraux Q, Tamm I, et al. A single BIR domain of XIAP sufficient for inhibiting caspases. J Biol Chem 1998; 273: 7787-7790.
142. Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 2009; 8: 2708-2710.
143. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
144. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003; 9: 4914-4925.
145. Schimmer AD, Pedersen IM, Kitada S, et al. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res 2003; 63: 1242-1248.
146. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-1803.
147. Sung KW, Choi J, Hwang YK, et al. Overexpression of X-linked inhibitor of apoptosis protein (XIAP) is an independent unfavorable prognostic factor in childhood de novo acute myeloid leukemia. J Korean Med Sci 2009; 24: 605-613.
148. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99: 1038-1043.
149. Ferreira CG, van der Valk P, Span SW, et al. Assessment of IAP (inhibitor of apoptosis) proteins as predictors of response to chemotherapy in advanced non-small-cell lung cancer patients. Ann Oncol 2001; 12: 799-805.
150. Hofmann HS, Simm A, Hammer A, Silber RE, Bartling B. Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol 2002; 128: 554-560.
151. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25-35.
152. Schimmer AD, Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy. Hematology Am Soc Hematol Educ Program 2005: 215-219.
153. Hu Y, Cherton-Horvat G, Dragowska V, et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9: 2826-2836.
154. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. J Biol Chem 2001; 276: 27058-27063.
155. Shiozaki EN, Chai J, Rigotti DJ, et al. Mechanism of XIAP-mediated inhibition of caspase-9. Mol Cell 2003; 11: 519-527.
156. Eckelman BP, Salvesen GS. The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 2006; 281: 3254-3260.
157. Broemer M, Meier P. Ubiquitin-mediated regulation of apoptosis. Trends Cell Biol 2009; 19: 130-140.
158. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA 2001; 98: 8662-8667.
159. Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
160. Schile AJ, Garcia-Fernandez M, Steller H. Regulation of apoptosis by XIAP ubiquitin-ligase activity. Genes Dev 2008; 22: 2256-2266.
161. Galban S, Duckett CS. XIAP as a ubiquitin ligase in cellular signaling. Cell Death Differ 2011; 17: 54-60.
162. Norberg E, Orrenius S, Zhivotovsky B. Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). Biochem Biophys Res Commun 2011; 396: 95-100.
163. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003; 115: 145-167.
164. Kim R, Emi M, Tanabe K. Role of mitochondria as the gardens of cell death. Cancer Chemother Pharmacol 2006; 57: 545-553.
165. Beisner DR, Ch'en IL, Kolla RV, Hoffmann A, Hedrick SM. Cutting edge: innate immunity conferred by B cells is regulated by caspase-8. J Immunol 2005; 175: 3469-3473.
166. Alladina SJ, Song JH, Davidge ST, Hao C, Easton AS. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res 2005; 42: 337-347.
167. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17: 1595-1606.
168. Gedaly R, Angulo P, Hundley J, et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010; 30: 4951-4958.
169. Dey JH, Bianchi F, Voshol J, et al. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 2010; 70: 4151-4162.
170. Darnell JE, Jr. STATs and gene regulation. Science 1997; 277: 1630-1635.
171. Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703.
172. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897-907.
173. Chu ZL, McKinsey TA, Liu L, et al. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci USA 1997; 94: 10057-10062.
174. Welters CF, Dejong CH, Deutz NE, Heineman E. Intestinal adaptation in short bowel syndrome. ANZ J Surg 2002; 72: 229-236.
175. Weisfelner ME, Gottlieb AB. The role of apoptosis in human epidermal keratinocytes. J Drugs Dermatol 2003; 2: 385-391.
176. Lenardo M, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999; 17: 221-253.
177. Toki T, Mori A, Shimizu M, Nikaido T, Fujii S. Localization of apoptotic cells within the human endometrium and correlation between apoptosis and p21 expression. Mol Hum Reprod 1998; 4: 1157-1164.
178. Ohsawa S, Hamada S, Kuida K, et al. Maturation of the olfactory sensory neurons by Apaf-1/caspase-9-mediated caspase activity. Proc Natl Acad Sci USA 2011; 107: 13366-13371.
179. Yan Q, Liu JP, Li DW. Apoptosis in lens development and pathology. Differentiation 2006; 74: 195-211.
180. Zhu N, Ware CF, Lai MM. Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. Virology 2001; 283: 178-187.
181. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107-1115.
182. Hickman ES, Bates S, Vousden KH. Perturbation of the p53 response by human papillomavirus type 16 E7. J Virol 1997; 71: 3710-3718.
183. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE, Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 1995; 133: 225-230.
184. Singh S, Dikshit M. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Brain Res Rev 2007; 54: 233-250.
185. Hickey MA, Chesselet MF. Apoptosis in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 255-265.
186. Ferreira IL, Nascimento MV, Ribeiro M, et al. Mitochondrial-dependent apoptosis in Huntington's disease human cybrids. Exp Neurol 2010; 222: 243-255.
187. Marshall KA, Daniel SE, Cairns N, Jenner P, Halliwell B. Upregulation of the anti-apoptotic protein Bcl-2 may be an early event in neurodegeneration: studies on Parkinson's and incidental Lewy body disease. Biochem Biophys Res Commun 1997; 240: 84-87.
188. Dowling P, Shang G, Raval S, et al. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med 1996; 184: 1513-1518.
189. Bonetti B, Raine CS. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997; 42: 74-84.
190. Green DR, Ware CF. Fas-ligand: privilege and peril. Proc Natl Acad Sci USA 1997; 94: 5986-5990.
191. Stassi G, De Maria R, Trucco G, et al. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186: 1193-1200.
192. Johnson JD, Luciani DS. Mechanisms of pancreatic beta-cell apoptosis in diabetes and its therapies. Adv Exp Med Biol 2011; 654: 447-462.
193. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375: 497-500.
194. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-1443.
195. Scopa CD, Vagianos C, Kardamakis D, et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol 2001; 9: 329-334.
196. Chi KN, Gleave ME, Klasa R, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7: 3920-3927.
197. Banerjee D. Genasense (Genta Inc). Curr Opin Investig Drugs 2001; 2: 574-580.
198. Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 2003; 30: 143-149.
199. Leber B, Geng F, Kale J, Andrews DW. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med 2011; 12: e28.
200. Fulda S. Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther 2007; 7: 1255-1264.
201. Hagg M, Biven K, Ueno T, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs 2002; 20: 253-259.
202. Biven K, Erdal H, Hagg M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003; 8: 263-268.
203. Demiray M, Ulukaya EE, Arslan M, et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 2006; 24: 669-676.
204. Takada M, Kataoka A, Toi M, et al. A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. Int J Oncol 2004; 25: 397-405.
205. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007; 56: 399-404.
206. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009; 13: 565-580.
207. Yilmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13: 837-844.